Innate Pharma S.A.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Innate Pharma S.A. (IPHA:EN Paris) is a clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company discovers and develops therapeutic antibodies targeting the innate immune system, including natural killer (NK) cell engagers and multispecific antibodies; its lead product candidate, IPH6501 (monalizumab), is a first-in-class anti-NKG2A antibody in Phase 3 trials for head and neck cancer in combination with other therapies; additional pipeline assets include IPH5301 (anti-CD39), IPH6208 (NKp46-based NK cell engager), and IPH6503 (anti-CD25); and it offers discovery services through its proprietary platforms such as the NK cell platform and antibody engineering technologies. Founded in 1999 and headquartered in Marseille, France, Innate Pharma operates primarily in Europe with clinical trials and partnerships extending to North America and Asia, targeting pharmaceutical companies and oncology patients through collaborations with major players like Sanofi and Bristol Myers Squibb. Recent developments include the advancement of IPH6501 into a Phase 3 trial in 2024 following positive Phase 2 data; a strategic licensing agreement with Sanofi for monalizumab development and commercialization rights in specific indications announced in late 2023; and the presentation of new preclinical data on IPH6208 at major oncology conferences in 2025, underscoring pipeline expansion amid ongoing cost-optimization measures.
Company News
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround
Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Stock Has Average Target Price of $6.67
Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know
Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript
Innate Pharma Q2 Earnings Call Highlights
Innate Pharma Reports First Half 2026 Business Update and Financial Results
Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions
Innate Pharma Secures €30M, Extends Cash Runway Into 2028
Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript
Innate Pharma Announces Conference Call and Webcast
Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
Innate Pharma: Pipeline Optionality Favors Speculative Bulls At These Levels
Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)
Outcome of Innate Pharma's 2026 Annual General Meeting